Details for Patent: 11,744,967
Which drugs does patent 11,744,967 protect, and when does it expire?
Patent 11,744,967 protects ATZUMI and is included in one NDA.
This patent has thirteen patent family members in eleven countries.
Summary for Patent: 11,744,967
| Title: | Intranasal delivery devices |
| Abstract: | The present disclosure provides devices for delivery of powder formulations and methods of manufacture and use of such devices. |
| Inventor(s): | Shunji Haruta |
| Assignee: | Shin Nippon Biomedical Laboratories Ltd |
| Application Number: | US16/137,852 |
|
Patent Claim Types: see list of patent claims | Use; Formulation; Delivery; Device; |
Drugs Protected by US Patent 11,744,967
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Satsuma Pharms | ATZUMI | dihydroergotamine mesylate | POWDER;NASAL | 217901-001 | Apr 30, 2025 | RX | Yes | Yes | 11,744,967 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,744,967
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2018343545 | ⤷ Start Trial | |||
| Brazil | 112020006016 | ⤷ Start Trial | |||
| Canada | 3076993 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
